Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled “Compositions for the treatment of skin conditions,” continues to strengthen Dermata’s global intellectual property portfolio for DMT410 for the treatment of hyperhidrosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA: